Holen Sie sich die Stockscreener-App
3.49
0.29%
-0.010
Handel nachbörslich:
3.49
Schlusskurs vom Vortag:
$3.50
Offen:
$3.44
24-Stunden-Volumen:
1.40M
Relative Volume:
1.67
Marktkapitalisierung:
$663.57M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-7.9318
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
+2.95%
1M Leistung:
+1.16%
6M Leistung:
-9.35%
1J Leistung:
+35.27%
1-Tages-Spanne:
$3.35
$3.54
1-Wochen-Bereich:
$3.20
$3.54
52-Wochen-Spanne:
$2.30
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.49 | 663.57M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters - BUCKSCO.Today
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MSN
Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Chardan Capital Reiterates “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Arbutus Biopharma earnings beat by $0.02, revenue fell short of estimates - Investing.com
Arbutus stock gains after 57% workforce cuts (ABUS:NASDAQ) - Seeking Alpha
Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? - uspostnews.com
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Arbutus Biopharma Announces 2024 Financial Results and Strategic Restructuring - TipRanks
Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery - MSN
Reviewing Akari Therapeutics (NASDAQ:AKTX) and Arbutus Biopharma (NASDAQ:ABUS) - Defense World
FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World
Are Arbutus Biopharma Corp’shares a good deal? - US Post News
Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360
Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire
Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq
Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan
Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
StockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Sell - MarketBeat
Brokers Issue Forecasts for ABUS FY2029 Earnings - MarketBeat
Brokers Set Expectations for ABUS FY2029 Earnings - Defense World
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo
Lindsay Androski named CEO of Arbutus - BioCentury
Arbutus Biopharma appoints new CEO and reshapes board - Investing.com
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times
Hepatitis B Market to Reach New Heights in Growth by 2032, - openPR.com
Arbutus Biopharma Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - Jomfruland.net
Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - MSN
Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR
10 Best Nasdaq Stocks Under $5 to Buy - Insider Monkey
SG Americas Securities LLC Purchases 16,250 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp (ABUS) Stock: A Look at the Monthly Trend - The News Heater
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 By Investing.com - Investing.com South Africa
Jefferies analysts upgrades a Buy rating for Arbutus Biopharma Corp (ABUS) - Knox Daily
Arbutus Biopharma Executives Sell Shares to Cover Tax Obligations - TradingView
Arbutus Biopharma Corp (ABUS) expanding its growth trajectory ahead - SETE News
Morgan Stanley Reduces Stake in Arbutus Biopharma Corp - GuruFocus
JPMorgan Chase & Co. Increases Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Ballentine Partners LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):